Abstract
This Patent Highlight explores advancements in pharmacology, focusing on the novel delivery and application of psychoactive substances. It highlights the development of transdermal formulations for psychoactive alkaloids, neuroenhancement techniques to augment emotional responses, and the intravenous infusion of psilocybin or psilocin for various therapeutic purposes. Additionally, it delves into the characterization and potential uses of crystalline forms of tryptamine derivatives. These innovations signify significant progress in drug delivery systems, neurostimulation methods, and the therapeutic use of psychedelic compounds, potentially revolutionizing the treatment of psychological and neurological disorders.
Important Compound Classes
Titles
Method and Apparatus for Neuroenhancement to Enhance Emotional Response; Transdermal Psychoactive Alkaloid Composition and Preparation Thereof; Administration of a Psychedelic Compound by Intravenous Infusion; and Tryptamine Derivatives
Patent Publication Numbers
US 2023/0191073 A1 (URL: https://patents.google.com/patent/US20230191073A1/en?oq=US+2023%2f0191073+A1);
US 2023/0390213 A1 (URL: https://patents.google.com/patent/US20230390213A1/en?oq=US+2023%2f0390213+A1);
WO 2023/220363 A1 (URL: https://patents.google.com/patent/WO2023220363A1/en?oq=WO+2023%2f220363+A1); and
WO 2023/250465 A2 (URL: https://patents.google.com/patent/WO2023250465A2/en?oq=WO+2023%2f250465+A2)
Publication Dates
June 22, 2023; December 7, 2023; November 16, 2023; and December 28, 2023
Priority Applications
US 17/971540; US 18/259697; GB 2207766.3; and US 63/368194
Priority Dates
October 21, 2022; December 21, 2021; May 26, 2022; and July 12, 2022
Inventors
Poltorak, A. (US 2023/0191073 A1); Moss, R.; Lightburn, B.; Ranken, L. (US 2023/0390213 A1); Dickinson, H.; Dickinson, P. A.; Parisi, N. (WO 2023/220363 A1); and Chadeayne, A. R. (WO 2023/250465 A2)
Assignee Companies
Neuroenhancement Lab, LLC, Suffern, New York, US (US 2023/0191073 A1); Psilo Scientific Ltd, Vancouver, CA (US 2023/0390213 A1); Reset Pharmaceuticals, Inc. [US/US], 241 Central Park West, Apt. 9a, New York, NY 10024, US; and Caamtech, Inc. [US/US], 58 East Sunset Way, Suite 208, Issaquah, WA 98027, US (WO 2023/250465 A2)
Disease Area
Neuropsychiatric diseases
Biological Target
5-HT2A receptor
Summary
The ongoing exploration of psychoactive substances plays a pivotal role in expanding our understanding of neurological functions and developing new therapeutic modalities. Recent patent literature reflects a significant interest in optimizing these compounds’ delivery mechanisms and pharmacological profiles to enhance their therapeutic efficacy and bioavailability.
One such innovative approach is detailed in the patent US 2023/0390213 A1, which introduces a transdermal composition of psychoactive alkaloids. Here, the employment of dephosphorylated alkaloids enhances skin absorption. This composition utilizes an alcohol-based carrier, permeation enhancers, and thickening agents to facilitate a controlled release through transdermal systems. This method effectively circumvents the limitations associated with oral routes, such as first-pass metabolism, thereby promising a more efficient delivery of psychoactive agents.
Another novel delivery method involves modulating brainwave patterns to augment emotional responses, as per patent application US 2023/0191073 A1. This technology harnesses noninvasive techniques to induce desired brainwave states that enhance the sensory experiences of art and virtual reality, offering potential therapeutic applications for mental health conditions related to emotional processing.
Intravenous infusion methods for psychedelic compounds such as psilocybin and psilocin are described in patent application WO 2023/220363 A1. This technique improves the pharmacokinetics of these substances—enhancing the onset, duration, and consistency of therapeutic effects. It is particularly promising for treating psychological conditions like depression and PTSD, providing a more controlled and efficient administration.
Patent application WO 2023/250465 A2 covers the development of crystalline forms of tryptamine derivatives. These new forms are characterized by enhanced stability and efficacy, critical for reliable drug delivery and therapeutic action. The crystalline structures facilitate a targeted interaction with neurotransmitter systems and have shown potential in treating neurological and psychological disorders.
A comparative analysis of these methods highlights distinct advantages in addressing specific therapeutic needs. For instance, the transdermal delivery system bypasses digestive metabolism, providing quicker systemic absorption, crucial for conditions requiring immediate relief. On the other hand, the precise control offered by intravenous delivery is invaluable for acute therapeutic interventions. Crystalline derivatives ensure sustained drug release, which is beneficial for chronic treatment regimens.
The cumulative advancements in the delivery and efficacy of psychoactive substances underscore a significant shift toward personalized medical treatments. These innovations not only promise to refine therapeutic outcomes but also aim to mitigate the complexities associated with traditional psychoactive drug therapies. As the field evolves, these novel delivery systems could revolutionize treatment paradigms across neuropsychiatry, enhancing the quality of life for patients with diverse neurological and psychological conditions. However, the full potential of these technologies will be realized only through continued research and comprehensive clinical evaluations to ensure safety and efficacy.
Key Structures
Biological Data
The table below shows psychoactive
topical gel made from dephosphorylatable alkaloids in the extract
that have been dephosphorylated during the extraction.
Recent Review Articles
The author declares no competing financial interest.
References
- Barksdale B. R.; Doss M. K.; Fonzo G. A.; Nemeroff C. B. The Mechanistic Divide in Psychedelic Neuroscience: An Unbridgeable Gap?. Neurotherapeutics 2024, 21, e00322. 10.1016/j.neurot.2024.e00322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Solaja I.; Haldane K.; Mason N.; Weiss B.; Xu X.; Xu M.; Nikolin S.; Jayasena T.; Millard M.; Brett J.; Bayes A.; Loo C. K.; Martin D. M. Who Are You After Psychedelics? A Systematic Review and a Meta-Analysis of the Magnitude of Long-Term Effects of Serotonergic Psychedelics on Cognition/Creativity, Emotional Processing and Personality. Neurosci. Biobehav. Rev. 2024, 158, 105570. 10.1016/j.neubiorev.2024.105570. [DOI] [PubMed] [Google Scholar]
- Tabaac B. J.; Shinozuka K.; Arenas A.; Beutler B. D.; Cherian K.; Evans V. D.; Fasano C.; Muir O. S. Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin. Am. J. Ther. 2024, 31, e121–e132. 10.1097/MJT.0000000000001724. [DOI] [PubMed] [Google Scholar]
- Weleff J.; Nunes J. C.; Costa G. P. A.; Sofuoglu M.; MacLean R. R.; De Aquino J. P. From Taboo to Treatment: The Emergence of Psychedelics in the Management of Pain and Opioid Use Disorder. Br. J. Clin. Pharmacol. 2024, 10.1111/bcp.16045. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rahman S. M.; Salem Y.; Hussain A. Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens. Dermatitis 2024, 10.1089/derm.2023.0292. [DOI] [PubMed] [Google Scholar]
- Romeo B.; Kervadec E.; Fauvel B.; Strika-Bruneau L.; Amirouche A.; Verroust V.; Piolino P.; Benyamina A. Safety and Risk Assessment of Psychedelic Psychotherapy: A Meta-Analysis and Systematic Review. Psychiatry Res. 2024, 335, 115880. 10.1016/j.psychres.2024.115880. [DOI] [PubMed] [Google Scholar]